Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
33 hedge funds and large institutions have $21.4M invested in Cellular Biomedicine Group, Inc. in 2015 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 5 closing their positions.
32% more capital invested
Capital invested by funds: $16.2M → $21.4M (+$5.18M)
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
13% less funds holding
Funds holding: 38 → 33 (-5)
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$274K |
| 2 |
State Street
Boston,
Massachusetts
|
+$240K |
| 3 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$197K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$168K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$138K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
-$81.3K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$81.2K |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$47.9K |
| 4 |
SEI Investments
Oaks,
Pennsylvania
|
-$27K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Creative Planning
Overland Park,
Kansas
| $6K | – | – | – |
|
27
BlackRock
New York
| $5K | – | – | – |
|
28
Bank of America
Charlotte,
North Carolina
| $5K | +$4.02K | +190 | +396% |
|
29
Morgan Stanley
New York
| $4K | -$22.4K | -1,059 | -84% |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $3K | -$81.2K | -3,842 | -97% |
|
|
MFS
31
MSI Financial Services
Springfield,
Massachusetts
| $2K | – | – | – |
|
32
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $141 | – | – | – |
|
|
33
SEI Investments
Oaks,
Pennsylvania
| – | -$27K | -1,600 | Closed |
|
|
34
UBS Group
Zurich,
Switzerland
| – | -$25K | -1,502 | Closed |
|
|
PAM
35
Panagora Asset Management
Boston,
Massachusetts
| – | -$22K | -1,325 | Closed |
|
36
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$10.3K | -488 | -98% |
|
37
Barclays
London,
United Kingdom
| – | -$1K | -51 | Closed |
|
CBMG Hedge Fund Activity: Q4 2015 in Review
33 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q4 2015, worth a combined $21.4M — up 32% from $16.2M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CBMG and 1 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 12 added.
The largest buyer was Vanguard Group, adding an estimated $274K. The largest seller was AQR Capital Management, cutting an estimated $81.3K.
- 33 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q4 2015, down from 38 in Q3 2015.
- Funds reported $21.4M of Cellular Biomedicine Group, Inc. stock for Q4 2015, up 32% quarter-over-quarter.
- 1 fund opened new Cellular Biomedicine Group, Inc. positions in Q4 2015 and 5 closed out, a net change of -4 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q4 2015 was Vanguard Group, an estimated $274K added.
- The largest Cellular Biomedicine Group, Inc. seller in Q4 2015 was AQR Capital Management, an estimated $81.3K sold.
Based on aggregated 13F filings for Q4 2015.